Tags

Type your tag names separated by a space and hit enter

Kinins as therapeutic agents in cardiovascular and renal diseases.
Curr Pharm Des. 2011; 17(25):2654-62.CP

Abstract

A fair amount of data indicates that bradykinin and lysyl-bradykinin exert arterial, cardiac and renal effects which afford protection against organ damage in diseases, especially in the settings of ischemia or diabetes. The concept of kinins acting as therapeutic agents is supported by the wide use of angiotensin I-converting enzyme (ACE) inhibitors. These inhibitors indeed potentiate kinin action by inhibiting kinin degradation. Experimental evidence strongly suggests that the cardiac and renal effects of ACE inhibitors are due, at least in part, to kinins. Angiotensin AT1 receptor antagonists act also partly through kinins. This paper reviews available evidence supporting a role for kinins in the therapeutic effect of current drugs. It then discusses the opportunity to develop new drugs based on kinin action. Direct activation of the kinin B2 receptor by pharmacological agonists might provide higher therapeutic benefit than existing kinin- potentiating drugs. Possible occurrence of side effects is however a concern.

Authors+Show Affiliations

INSERM U872, Paris. francois.alhenc-gelas@inserm.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21728987

Citation

Alhenc-Gelas, Francois, et al. "Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases." Current Pharmaceutical Design, vol. 17, no. 25, 2011, pp. 2654-62.
Alhenc-Gelas F, Bouby N, Richer C, et al. Kinins as therapeutic agents in cardiovascular and renal diseases. Curr Pharm Des. 2011;17(25):2654-62.
Alhenc-Gelas, F., Bouby, N., Richer, C., Potier, L., Roussel, R., & Marre, M. (2011). Kinins as therapeutic agents in cardiovascular and renal diseases. Current Pharmaceutical Design, 17(25), 2654-62.
Alhenc-Gelas F, et al. Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases. Curr Pharm Des. 2011;17(25):2654-62. PubMed PMID: 21728987.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Kinins as therapeutic agents in cardiovascular and renal diseases. AU - Alhenc-Gelas,Francois, AU - Bouby,Nadine, AU - Richer,Christine, AU - Potier,Louis, AU - Roussel,Ronan, AU - Marre,Michel, PY - 2010/12/10/received PY - 2010/03/21/accepted PY - 2011/7/7/entrez PY - 2011/7/7/pubmed PY - 2012/3/16/medline SP - 2654 EP - 62 JF - Current pharmaceutical design JO - Curr. Pharm. Des. VL - 17 IS - 25 N2 - A fair amount of data indicates that bradykinin and lysyl-bradykinin exert arterial, cardiac and renal effects which afford protection against organ damage in diseases, especially in the settings of ischemia or diabetes. The concept of kinins acting as therapeutic agents is supported by the wide use of angiotensin I-converting enzyme (ACE) inhibitors. These inhibitors indeed potentiate kinin action by inhibiting kinin degradation. Experimental evidence strongly suggests that the cardiac and renal effects of ACE inhibitors are due, at least in part, to kinins. Angiotensin AT1 receptor antagonists act also partly through kinins. This paper reviews available evidence supporting a role for kinins in the therapeutic effect of current drugs. It then discusses the opportunity to develop new drugs based on kinin action. Direct activation of the kinin B2 receptor by pharmacological agonists might provide higher therapeutic benefit than existing kinin- potentiating drugs. Possible occurrence of side effects is however a concern. SN - 1873-4286 UR - https://www.unboundmedicine.com/medline/citation/21728987/Kinins_as_therapeutic_agents_in_cardiovascular_and_renal_diseases_ L2 - http://www.eurekaselect.com/75214/article DB - PRIME DP - Unbound Medicine ER -